Table 2 The correlation between serum lncRNA GAS5 and miR-21 and clinical and pathological parameters in patients with DN
Clinical and pathological parameters | Cases (%) | lncRNA GAS5 | miR-21 | ||
|---|---|---|---|---|---|
Stratifications | \(\bar x \pm {\text{s}}\) | P | \(\bar x \pm {\text{s}}\) | P | |
24 h UTP(g) | 25(100) | ||||
24 h UTP < 3.5 | 5(20) | 0.00 ± 0.00 | 0.028 | 1.35 ± 0.71 | 0.552 |
3.5 ≤ 24 h UTP<8.0 | 15(60) | 0.01 ± 0.00 | 1.68 ± 1.08 | ||
24 h UTP ≥ 8.0 | 5(20) | 0.01 ± 0.01 | 2.06 ± 1.07 | ||
CKD stages | 25(100) | ||||
CKD1 | 8(32) | 0.00 ± 0.00 | 0.238 | 1.60 ± 1.15 | 0.941 |
CKD2 | 8(32) | 0.01 ± 0.00 | 1.77 ± 1.14 | ||
CKD3-4 | 9(36) | 0.01 ± 0.01 | 1.70 ± 0.85 | ||
HbAlc(%) | 25(100) | ||||
HbAlc ≤ 6.5 | 8(32) | 0.01 ± 0.01 | 0.185 | 1.44 ± 1.16 | 0.398 |
HbAlc > 6.5 | 17(68) | 0.01 ± 0.00 | 1.81 ± 1.05 | ||
Pathological grading of renal biopsy | 25(100) | ||||
Type IIb | 2(8) | 0.01 ± 0.00 | 0.820 | 0.57 ± 0 | 0.038 |
Type III | 19(76) | 0.01 ± 0.01 | 1.97 ± 1.00 | ||
Type IV | 4(16) | 0.01 ± 0.00 | 0.94 ± 0.12 | ||
Age | 25(100) | ||||
18 ~ < 40 | 10(40) | 0.01 ± 0.01 | 0.56 | 1.56 ± 0.97 | 0.874 |
40~<50 | 4(16) | 0.01 ± 0.00 | 1.75 ± 0.83 | ||
50 ~ < 60 | 11(44) | 0.01 ± 0.00 | 1.79 ± 1.16 |